Literature DB >> 3500961

The Leu-1 B-cell subpopulation in patients with rheumatoid arthritis.

O Taniguchi1, H Miyajima, T Hirano, M Noguchi, A Ueda, H Hashimoto, S Hirose, K Okumura.   

Abstract

Ly-1-B cells have been shown to be elevated in autoimmune mice, especially NZB, and to secrete IgM autoantibody, suggesting that Ly-1 B cells may participate in autoimmune diseases. In this study, B-cell populations carrying Leu-1, a human T-cell surface molecule homologous to mouse Ly-1 (Leu-1 B), were examined by dual fluorescence flow cytometry, in peripheral blood lymphocytes taken from patients suffering from various autoimmune disease. These B cells were shown to be present at a significantly high percentage in rheumatoid arthritis (RA) patients. There was no significant correlation among the incidence of Leu-1 B cells, rheumatoid factor (RF) titers, and the amount of IgM production in vitro. There was, however, a significantly high incidence of Leu-1 B cells in RA patients with a high RF titer (greater than 5 X 2(13), suggesting that these B cells in RA may play an important role in IgM RF production in vivo.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3500961     DOI: 10.1007/BF00915053

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  17 in total

1.  1958 Revision of diagnostic criteria for rheumatoid arthritis.

Authors:  M W ROPES; G A BENNETT; S COBB; R JACOX; R A JESSAR
Journal:  Bull Rheum Dis       Date:  1958-12

2.  In vitro synthesis of IgM rheumatoid factor by lymphocytes from healthy adults.

Authors:  W J Koopman; R E Schrohenloher
Journal:  J Immunol       Date:  1980-08       Impact factor: 5.422

3.  B-cell subpopulations identified by two-colour fluorescence analysis.

Authors:  R R Hardy; K Hayakawa; J Haaijman; L A Herzenberg
Journal:  Nature       Date:  1982-06-17       Impact factor: 49.962

4.  Rheumatoid factor secretion from human Leu-1+ B cells.

Authors:  R R Hardy; K Hayakawa; M Shimizu; K Yamasaki; T Kishimoto
Journal:  Science       Date:  1987-04-03       Impact factor: 47.728

5.  Ly-1 B cells: functionally distinct lymphocytes that secrete IgM autoantibodies.

Authors:  K Hayakawa; R R Hardy; M Honda; L A Herzenberg; A D Steinberg; L A Herzenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

6.  Expression of Lyt-1 by a subset of B lymphocytes.

Authors:  V Manohar; E Brown; W M Leiserson; T M Chused
Journal:  J Immunol       Date:  1982-08       Impact factor: 5.422

7.  Expression of Lyt-1 antigen on certain murine B cell lymphomas.

Authors:  L L Lanier; N L Warner; J A Ledbetter; L A Herzenberg
Journal:  J Exp Med       Date:  1981-04-01       Impact factor: 14.307

8.  Infrequent normal B lymphocytes express features of B-chronic lymphocytic leukemia.

Authors:  F Caligaris-Cappio; M Gobbi; M Bofill; G Janossy
Journal:  J Exp Med       Date:  1982-02-01       Impact factor: 14.307

9.  Phenotype of recovering lymphoid cell populations after marrow transplantation.

Authors:  K A Ault; J H Antin; D Ginsburg; S H Orkin; J M Rappeport; M L Keohan; P Martin; B R Smith
Journal:  J Exp Med       Date:  1985-06-01       Impact factor: 14.307

10.  Identification of a p69,71 complex expressed on human T cells sharing determinants with B-type chronic lymphatic leukemic cells.

Authors:  C Y Wang; R A Good; P Ammirati; G Dymbort; R L Evans
Journal:  J Exp Med       Date:  1980-06-01       Impact factor: 14.307

View more
  18 in total

1.  Pulsed high-dose dexamethasone improves interleukin 10 secretion by CD5+ B cells in patients with primary immune thrombocytopenia.

Authors:  Fanli Hua; Lili Ji; Yanxia Zhan; Feng Li; Shanhua Zou; Xiaoyun Wang; Dongli Song; Zhihui Min; Song Gao; Yangjiong Wu; Hao Chen; Yunfeng Cheng
Journal:  J Clin Immunol       Date:  2012-06-06       Impact factor: 8.317

2.  Autoantibodies to brain and polynucleotides in patients with schizophrenia: a puzzle.

Authors:  H A Teplizki; B Sela; Y Shoenfeld
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

3.  Normal human intestinal B lymphocytes. Increased activation compared with peripheral blood.

Authors:  M G Peters; H Secrist; K R Anders; G S Nash; S R Rich; R P MacDermott
Journal:  J Clin Invest       Date:  1989-06       Impact factor: 14.808

4.  Anti-DNA antibody production by CD5+ and CD5- B cells of patients with systemic lupus erythematosus.

Authors:  N Suzuki; T Sakane; E G Engleman
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

5.  Aberrant T-regulation in rheumatoid arthritis and IgA nephropathy affects CD5+ and CD5- B lymphocytes equally.

Authors:  B M Jones; I K Cheng; R W Wong
Journal:  Clin Exp Immunol       Date:  1991-11       Impact factor: 4.330

6.  Autoantibodies to T and B cell lines detected in serum samples from patients with systemic lupus erythematosus with lymphopenia and hypocomplementaemia.

Authors:  M Noguchi; M Iwamori; T Hirano; S Kobayashi; H Hashimoto; S Hirose; Y Nagai
Journal:  Ann Rheum Dis       Date:  1992-06       Impact factor: 19.103

7.  FcμR in human B cell subsets in primary selective IgM deficiency, and regulation of FcμR and production of natural IgM antibodies by IGIV.

Authors:  Sudhir Gupta; Sudhanshu Agrawal; Sastry Gollapudi; Hiromi Kubagawa
Journal:  Hum Immunol       Date:  2016-10-14       Impact factor: 2.850

8.  Comparable profiles of the immunoglobulin heavy chain complementarity determining region (CDR)-3 in CD5+ and CD5- human cord blood B lymphocytes.

Authors:  H Kiyoi; K Naito; R Ohno; T Naoe
Journal:  Immunology       Date:  1995-06       Impact factor: 7.397

Review 9.  B lymphocytes and humoral immune responses in rheumatoid arthritis.

Authors:  L S De Clerck
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

10.  Immunoglobulin heavy chain variable region gene utilization by B cell hybridomas derived from rheumatoid synovial tissue.

Authors:  C M Brown; C Longhurst; G Haynes; C Plater-Zyberk; A Malcolm; R N Maini
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.